On March 27, Cinda Biopharmaceutical Group's official website announced that IBI310 (anti-CTLA-4 monoclonal antibody) combined with cindilimab (PD-1 inhibitor) as a new adjuvant treatment for resectable microsatellites with highly unstable or mismatched repair protein defects (Msi-H/dmmr) colon cancer (CT4 or CN+ stage) has completed the first randomized, controlled, and multicenter clinical study (Neosshot) in patients with colon cancer (CT4 or CN+ stage) in China.
信达生物：IBI310结肠癌新辅助III期临床研究完成首例受试者给药
Innovent Biotech: IBI310 Colon Cancer Newly Adjuvant Phase III Clinical Study Completed First Patient Dosing
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.